A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

IsraelRecruitingPHASE1

Conditions

Advanced Solid Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States

    Study coordinator · 813-745-5995
  • START Midwest ( Site 0267), Grand Rapids, Michigan, United States

    Study coordinator · 616-954-5554
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States

    Study coordinator · 551-996-5900
  • Laura and Isaac Perlmutter Cancer Center ( Site 0270), New York, New York, United States

  • NEXT Virginia ( Site 0271), Fairfax, Virginia, United States

    Study coordinator · 703-280-5390
  • MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0262), Milwaukee, Wisconsin, United States

    Study coordinator · 414-805-0505
  • Instituto Alexander Fleming ( Site 0434), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

    Study coordinator · +541132218900
  • Sanatorio Parque ( Site 0456), Rosario, Santa Fe Province, Argentina

    Study coordinator · 5493416955611
  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0438), La Rioja, Argentina

    Study coordinator · +549380 4425438
  • Chris O'Brien Lifehouse ( Site 0002), Camperdown, New South Wales, Australia

    Study coordinator · 61285140162
  • Liverpool Hospital-Medical Oncology ( Site 0001), Liverpool, New South Wales, Australia

    Study coordinator · 61287389744
  • Westmead Hospital ( Site 0006), Westmead, New South Wales, Australia

    Study coordinator · +61403170371
  • Monash Health-Oncology Research ( Site 0003), Clayton, Victoria, Australia

    Study coordinator · 6385722429
  • Cross Cancer Institute ( Site 0033), Edmonton, Alberta, Canada

    Study coordinator · 780-908-8213
  • The Moncton Hospital ( Site 0037), Moncton, New Brunswick, Canada

    Study coordinator · 506-857-5104
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0030), Hamilton, Ontario, Canada

    Study coordinator · 905-387-9495
  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0036), Kingston, Ontario, Canada

    Study coordinator · 613-549-6666x4502
  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0032), Toronto, Ontario, Canada

    Study coordinator · 416-946-4501
  • James Lind Centro de Investigacion del Cancer ( Site 0043), Temuco, Araucania, Chile

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0041), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56 9 9161 2199
  • FALP-UIDO ( Site 0040), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56981369487
  • Bradfordhill ( Site 0042), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56998744662
  • Beijing Friendship Hospital Affiliate of Capital University-Oncology ( Site 0417), Beijing, Beijing Municipality, China

    Study coordinator · 01063138585
  • Fujian Cancer Hospital ( Site 0419), Fuzhou, Fujian, China

    Study coordinator · 0591-62752500
  • Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 0413), Guangzhou, Guangdong, China

    Study coordinator · 8620 62787110
  • Sun Yat-sen University Cancer Center-Internal medicine ( Site 0415), Guangzhou, Guangdong, China

    Study coordinator · 86 02087343801
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0418), Wuhan, Hubei, China

    Study coordinator · 027-85726685
  • Jilin Cancer Hospital-oncology department ( Site 0412), Changchun, Jilin, China

  • Shanghai Chest Hospital-Oncology department ( Site 0410), Shanghai, Shanghai Municipality, China

    Study coordinator · 021-22200000
  • Shanghai East Hospital ( Site 0416), Shanghai, Shanghai Municipality, China

    Study coordinator · +86 13764694939
  • Zhejiang Cancer Hospital-Thoracic oncology ( Site 0411), Hangzhou, Zhejiang, China

    Study coordinator · 0571-88122092
  • Odense Universitetshospital-Department of oncology ( Site 0421), Odense, Region Syddanmark, Denmark

    Study coordinator · +45 66113333
  • Rambam Health Care Campus-Oncology ( Site 0090), Haifa, Israel

    Study coordinator · +97247776234
  • Shaare Zedek Medical Center-Oncology ( Site 0092), Jerusalem, Israel

    Study coordinator · +97226555768
  • Hadassah Medical Center-Oncology ( Site 0094), Jerusalem, Israel

    Study coordinator · +97226776760
  • Meir Medical Center. ( Site 0091), Kfar Saba, Israel

    Study coordinator · 97297472414
  • Sheba Medical Center-ONCOLOGY ( Site 0093), Ramat Gan, Israel

    Study coordinator · +97235304498
  • Humanitas ( Site 0113), Rozzano, Lombardy, Italy

    Study coordinator · 00390282244559
  • ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 0111), Siena, Tuscany, Italy

    Study coordinator · 00390577586335
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0110), Naples, Italy

    Study coordinator · 08117770810
  • National Cancer Center Hospital East ( Site 0404), Kashiwa, Chiba, Japan

    Study coordinator · +81-4-7133-1111
  • Kanagawa Cancer Center ( Site 0402), Yokohama, Kanagawa, Japan

    Study coordinator · +81-45-520-2222
  • Shizuoka Cancer Center ( Site 0401), Nakatogari, Shizuoka, Japan

    Study coordinator · +81-55-989-5222
  • National Cancer Center Hospital ( Site 0403), Chuo-ku, Tokyo, Japan

    Study coordinator · +81-3-3542-2511
  • Cancer Institute Hospital of JFCR ( Site 0400), Koto, Tokyo, Japan

    Study coordinator · +81-3-3520-0111
  • Hospital of Lithuanian University of Health Sciences Kauno klinikos ( Site 0121), Kaunas, Kaunas County, Lithuania

    Study coordinator · +370 600 04799
  • Vilnius University Hospital Santaros Clinics Affiliate - National Cancer Center ( Site 0120), Vilnius, Lithuania

    Study coordinator · +37064565101
  • Sarawak General Hospital ( Site 0453), Kuching, Sarawak, Malaysia

    Study coordinator · 082-276666
  • New Zealand Clinical Research (Christchurch) ( Site 0004), Christchurch, Canterbury, New Zealand

  • Centro Oncologico de Panama ( Site 0160), Panama City, Panama

    Study coordinator · +50764807461
  • Centro Hemato Oncológico Paitilla ( Site 0163), Panama City, Panama

  • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0172), Poznan, Greater Poland Voivodeship, Poland

    Study coordinator · 48606228277
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 0170), Warsaw, Masovian Voivodeship, Poland

    Study coordinator · 48225463381
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0171), Gdansk, Pomeranian Voivodeship, Poland

    Study coordinator · 48585844571
  • Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej ( Site 0173), Koszalin, West Pomeranian Voivodeship, Poland

    Study coordinator · +48 94 348 84 00
  • Seoul National University Hospital ( Site 0191), Seoul, South Korea

    Study coordinator · 82220722995
  • Samsung Medical Center-Division of Hematology/Oncology ( Site 0193), Seoul, South Korea

    Study coordinator · +82-2-3410-3459
  • Clinica Universidad de Navarra ( Site 0213), Madrid, Madrid, Comunidad de, Spain

    Study coordinator · 34913531920x7501
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0211), Madrid, Madrid, Comunidad de, Spain

    Study coordinator · 34 91 550 48 00x2689
  • Hospital Universitari Vall d'Hebron-Oncology ( Site 0212), Barcelona, Spain

    Study coordinator · 34 93 274 60 00x6988
  • Cantonal Hospital St.Gallen ( Site 0224), Sankt Gallen, Canton of St. Gallen, Switzerland

    Study coordinator · 071/494 11 11
  • Ospedale Regionale Bellinzona e Valli ( Site 0220), Bellinzona, Canton Ticino, Switzerland

    Study coordinator · 41918118045
  • Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 0445), Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan

    Study coordinator · 886-7-7317123
  • National Cheng Kung University Hospital ( Site 0444), Tainan, Taiwan

    Study coordinator · +88662353535
  • National Taiwan University Hospital-Oncology ( Site 0443), Taipei, Taiwan

    Study coordinator · +886223123456
  • Ege University Medicine of Faculty ( Site 0231), Bornova, İzmir, Turkey (Türkiye)

  • Erciyes University ( Site 0232), Talas, Kayseri, Turkey (Türkiye)

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 0234), Ankara, Turkey (Türkiye)

    Study coordinator · 905334318506
  • Ankara City Hospital-oncology ( Site 0233), Ankara, Turkey (Türkiye)

    Study coordinator · +90 312 552 60 00
  • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 0254), Cherkasy, Cherkasy Oblast, Ukraine

    Study coordinator · +380472370123
  • Communal Non-Commercial Enterprise Prykarpatski Clinical Onc-Chemotherapy department ( Site 0251), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

    Study coordinator · +380502094000
  • Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 0255), Kropyvnytskyi, Kirovohrad Oblast, Ukraine

    Study coordinator · +380522366001
  • Rivne Regional Clinical Hospital ( Site 0257), Rivne, Rivne Oblast, Ukraine

  • ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 0259), Rivne, Rivne Oblast, Ukraine

    Study coordinator · +380503802915
  • Uzhhorod Multispecialty City Clinical Hospital ( Site 0258), Uzhhorod, Zakarpattia Oblast, Ukraine

    Study coordinator · +380312642332
Study leads
  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC